Ref13P6
Free Rad.
Res. Comms., Vol. 11, Nos. 1-3, pp.109-115
Studies on the Antioxidant and Free Radical Scavenging Properties
of IdB 1016 (Siliphos®) A New Flavanolignan Complex
A. Comoglio, G. Leonarduzzi, R. Carini, D. Busolin, H. Basaga*,
E. Albano, A. Tomasi**, G. Poli, P. Morazzoni***, and M.J. Magistretti
*Department of Experimental Medicine and Oncology, University
of Turin, **Institute of General Pathology, University of Modena
and ***Inverni della Beffa Research and Development Laboratories,
Milan, Italy
See
National Library of Medicine Citation
Flavonoids are a wide group of plant-derived compounds which have
been demonstrated to have antihepatotoxic effects. Among the flavonoids
the purified extract of Silybum marianum (silymarin) and its main
active constituent silybin have received substantial attention
because of their antioxidant properties.
Nonetheless, the possible application of these flavonoids in therapy
is hampered by their low solubility in water and by the poor enteral
absorption. In order to increase absorption silybin has been complexed
on a molecular level with phosphatidylcholine to create IdB 1016
(Siliphos®). After oral administration of IdB 1016 (Siliphos®)
to rats the plasma levels of silybin were found to be significantly
higher than those present after the administration of either uncomplexed
silybin or silymarin to humans (1).
In conclusion of this study it was found that IdB 1016 (Siliphos®)
is able to reach intracellular sites at concentrations which make
it effective as an antioxidant. It was also proven to target the
liver preferentially. Also, the fact that it is capable of scavenging
free radicals and inhibit lipid peroxidation suggests that this
compound may be potentially useful to protect against free radical-mediated
toxic damage.
1. N. Barzaghi, G. Perucca, G. Pifferi and A. Crema, (1989) Single-dose
pharmacokinetic study of IdB 1016 (Siliphos®), a new flavanolignan
complex in man. European Journal of Clinical Pharmacology, 36 (suppl.),
A110
|